Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls

Mild hyperhomocysteinemia has been considered a cardiovascular risk factor. However, recent prospective studies have not demonstrated that hyperhomocysteinemia or the underlying genetic defect on methylentetrahydrofolate reductase is associated with a higher risk of coronary or peripheral artery disease. We compared serum homocysteine, folate, and vitamin B12 levels of patients with coronary and peripheral vascular disease with those of age- and sex-matched healthy individuals. Subjects taking multivitamins, with diabetes mellitus, or serum creatinine levels over 1.5 mg/dL were excluded from the study. Homocysteine was measured by fluorimetric high-performance liquid chromatography. Serum folate and vitamin B12 levels were measured by an ion-capture method. We studied 32 patients with peripheral vascular disease (10 female), aged 69.6 ± 11 y, 24 age- and sex-matched control subjects, 52 patients with coronary artery disease (7 female), aged 59.5 ± 10.4 y, and 42 age- and sex-matched control subjects. Serum homocysteine levels were 11.7 ± 7.4 and 9.3 ± 4.5 μmol/L in vascular patients and in the control counterparts, respectively (not significant). The levels for coronary patients and the control counterparts were 9.0 ± 3.9 and 8.6 ± 3.6 μmol/L, respectively (not significant). Folate levels were 4.48 ± 2.42 and 7.14 ± 4.04 ng/mL in vascular patients and control subjects, respectively (P < 0.02); the levels in coronary patients and control counterparts were 5.15 ± 1.9 and 6.59 ± 2.49 ng/mL, respectively (P < 0.01). No differences in vitamin B12 or tocopherol levels were observed between patients and control subjects. There were no differences in homocysteine levels, but lower serum folate levels were observed when comparing patients with atherosclerotic vascular disease and healthy control subjects.